Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued ...

Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage ...

It's all about winning. Tennessee was one of the first states to push for NIL rights for athletes and this is an extension of that strategy.

Victory Capital Management Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) ...

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a Latin American licensed producer of medicinal cannabis and ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic ...

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

WHAT’S IN HER BAG? WOMEN’S ESSENTIALS FOR A DAY ON THE GOLF COURSE Find your golf essentials at The Mall at Millenia, which ...

Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance ...